Testing an NTRK-fusion drug for advanced tumors
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1/2 study tests ICP-723, a medicine designed to treat cancers that have an NTRK gene fusion. It may help shrink tumors in people whose cancer test shows this specific genetic change and who haven’t taken an NTRK inhibitor before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your overall health is good (ECOG 0–1), meaning you can do most daily activities
- Your tumor test shows an NTRK gene fusion from the study’s central lab
- You have not taken an NTRK inhibitor before
- You have at least one measurable tumor area doctors can track with scans
- Your heart rhythm and organ health (blood, liver, kidneys, etc.) meet study limits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ICP-B794 in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if the drug is safe and effective, and it may help shrink tumors or slow their growth.
This trial studies ICP-723 (a new medicine) in people with advanced cancers that cannot be removed with surgery, and in some primary brain (CNS) tumors. It’s an early-phase study (Phase 1/2) to see how the treatment works and how safe it is.
This trial tests a new daily pill (CG001419) for people with advanced solid tumors that have specific changes in the NTRK gene or TRK protein. The study aims to see if the drug is safe and effective, especially in those whose cancers have not responded to other treatments.
This trial tests an experimental pill called TL118 for people whose solid tumors have a specific NTRK gene fusion. It aims to see if the drug can shrink tumors or slow their growth when other treatments have stopped working or aren't an option.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests an investigational drug, SNH-118110, for people with advanced solid tumors that have a specific genetic change called RET. It aims to see if the drug can shrink tumors or slow their growth.
Hear when a new Advanced Solid Tumors Harboring NTRK Fusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.